| __timestamp | CRISPR Therapeutics AG | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 1244910 |
| Thursday, January 1, 2015 | 13403000 | 5029636 |
| Friday, January 1, 2016 | 31056000 | 4846776 |
| Sunday, January 1, 2017 | 35845000 | 5329003 |
| Monday, January 1, 2018 | 48294000 | 7121000 |
| Tuesday, January 1, 2019 | 63488000 | 9128000 |
| Wednesday, January 1, 2020 | 88208000 | 10731000 |
| Friday, January 1, 2021 | 102802000 | 10701000 |
| Saturday, January 1, 2022 | 102464000 | 16121000 |
| Sunday, January 1, 2023 | 76162000 | 37021000 |
| Monday, January 1, 2024 | 72977000 |
Unleashing the power of data
In the dynamic world of biotechnology, operational costs are a critical factor in determining a company's financial health. Over the past decade, from 2014 to 2023, the Selling, General, and Administrative (SG&A) expenses of CRISPR Therapeutics AG and Viking Therapeutics, Inc. have shown intriguing trends. CRISPR Therapeutics AG, a leader in gene-editing technology, saw its SG&A expenses grow by over 1,400% from 2014 to 2021, peaking in 2021 before a slight decline in 2023. In contrast, Viking Therapeutics, Inc., known for its focus on metabolic and endocrine disorders, experienced a more modest increase of approximately 200% over the same period, with a notable spike in 2023. This divergence highlights the varying strategic approaches and market pressures faced by these companies. As the biotech landscape evolves, understanding these cost dynamics is essential for investors and industry stakeholders.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
AstraZeneca PLC vs Viking Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Amgen Inc. vs Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Zoetis Inc. vs CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? Genmab A/S or Viking Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Viking Therapeutics, Inc.
Intra-Cellular Therapies, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Catalent, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Viking Therapeutics, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viking Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?